Assignee
KYOWA KIRIN CO LTD
JP·35 granted patents·34 pending applications·14 citations·filing 2015–2025
Top patents by PatentIndex Score
69 records- 0188US12054494B2Compound with anticancer activityKYOWA KIRIN CO LTD·Filed 2023·Granted Aug 6, 2024·1 cites·5 claims
- 0288US11192953B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKYOWA KIRIN CO LTD·Filed 2018·Granted Dec 7, 2021·2 cites·25 claims
- 0384US12297268B2Antibody which binds to myelin oligodendrocyte glycoproteinKYOWA KIRIN CO LTD·Filed 2023·Granted May 13, 2025·0 cites·12 claims
- 0482US11117963B2Antibody which binds to myelin oligodendrocyte glycoproteinKYOWA KIRIN CO LTD·Filed 2017·Granted Sep 14, 2021·1 cites·8 claims
- 0579US12319741B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKYOWA KIRIN CO LTD·Filed 2021·Granted Jun 3, 2025·0 cites·17 claims
- 0679US10787428B2α,β-unsaturated amide compoundKYOWA KIRIN CO LTD·Filed 2016·Granted Sep 29, 2020·2 cites·19 claims
- 0779US10745700B2Nucleic acid conjugateKYOWA KIRIN CO LTD·Filed 2017·Granted Aug 18, 2020·3 cites·8 claims
- 0879US2026092110A1Antibody which binds to myelin oligodendrocyte glycoproteinKYOWA KIRIN CO LTD·Filed 2025·Application pending·0 cites
- 0978US12251446B2Nucleic acid conjugateKYOWA KIRIN CO LTD·Filed 2017·Granted Mar 18, 2025·2 cites·12 claims
- 1077US2024059788A1BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAMKYOWA KIRIN CO LTD·Filed 2023·Application pending·0 cites
- 1176US2024360149A1Compound with anticancer activityKYOWA KIRIN CO LTD·Filed 2024·Application pending·0 cites
- 1276US2023218612A1Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenineKYOWA KIRIN CO LTD·Filed 2023·Application pending·0 cites
- 1374US11629152B2Compound with anticancer activityKYOWA KIRIN CO LTD·Filed 2019·Granted Apr 18, 2023·1 cites·19 claims
- 1473US12187803B2Bispecific antibody that binds to CD116 and CD131KYOWA KIRIN CO LTD·Filed 2024·Granted Jan 7, 2025·0 cites·14 claims
- 1573US2023250401A1Method for selecting cellKYOWA KIRIN CO LTD·Filed 2023·Application pending·0 cites
- 1672US11873337B2Antibody binding to cell adhesion molecule 3KYOWA KIRIN CO LTD·Filed 2019·Granted Jan 16, 2024·1 cites·29 claims
- 1772US10894043B2Pharmaceutical compositionKYOWA KIRIN CO LTD·Filed 2017·Granted Jan 19, 2021·1 cites·19 claims
- 1872US2024262903A1Methods for treating hypertension using an anti-bmp10 monoclonal antibody or fragment thereofKYOWA KIRIN CO LTD·Filed 2024·Application pending·0 cites
- 1971US2025092148A1Bispecific antibody that binds to cd116 and cd131KYOWA KIRIN CO LTD·Filed 2024·Application pending·0 cites
- 2070US11970531B2Methods for treating hypertension using an anti-BMP10 monoclonal antibody or fragment thereofKYOWA KIRIN CO LTD·Filed 2022·Granted Apr 30, 2024·0 cites·6 claims
- 2170US2022025044A1Antibody which binds to myelin oligodendrocyte glycoproteinKYOWA KIRIN CO LTD·Filed 2021·Application pending·0 cites
- 2269US2024207246A1Pharmaceutical compositionKYOWA KIRIN CO LTD·Filed 2024·Application pending·0 cites
- 2368US2024026017A1Anti-human ccr1 monoclonal antibodyKYOWA KIRIN CO LTD·Filed 2023·Application pending·0 cites
- 2466US11999788B2Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibodyKYOWA KIRIN CO LTD·Filed 2021·Granted Jun 4, 2024·0 cites·10 claims
- 2566US2020179376A1Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenineKYOWA KIRIN CO LTD·Filed 2019·Application pending·0 cites
- 2665US12258413B2Bispecific antibody binding to TfRKYOWA KIRIN CO LTD·Filed 2019·Granted Mar 25, 2025·0 cites·10 claims
- 2765US11773180B2Bispecific antibody which binds to CD40 and EpCAMKYOWA KIRIN CO LTD·Filed 2018·Granted Oct 3, 2023·0 cites·18 claims
- 2865US2025250352A1BISPECIFIC ANTIBODY BINDING TO TfRKYOWA KIRIN CO LTD·Filed 2025·Application pending·0 cites
- 2963US2024191179A1Method for suppressing production of degradation productsKYOWA KIRIN CO LTD·Filed 2022·Application pending·0 cites
- 3063US2026070891A1Method for producing quinoxaline derivativeKYOWA KIRIN CO LTD·Filed 2023·Application pending·0 cites
- 3161US11773161B2Anti-bril antibodyKYOWA KIRIN CO LTD·Filed 2021·Granted Oct 3, 2023·0 cites·2 claims
- 3261US10894790B2Production method of thiazole derivativeKYOWA KIRIN CO LTD·Filed 2020·Granted Jan 19, 2021·0 cites·19 claims
- 3360US11951103B2Pharmaceutical compositionKYOWA KIRIN CO LTD·Filed 2020·Granted Apr 9, 2024·0 cites·33 claims
- 3460US2020247798A1Therapeutic agent for anxiety disordersKYOWA KIRIN CO LTD·Filed 2020·Application pending·0 cites
- 3559US2023383001A1Method for treating ox40 related diseaseKYOWA KIRIN CO LTD·Filed 2021·Application pending·0 cites
- 3659US2024325426A1Polynucleotide and pharmaceutical compositionKYOWA KIRIN CO LTD·Filed 2022·Application pending·0 cites
- 3758US11485779B2Anti-BMP10 monoclonal antibody or fragment thereofKYOWA KIRIN CO LTD·Filed 2018·Granted Nov 1, 2022·0 cites·7 claims
- 3856US11332455B2α,β-unsaturated amide compoundKYOWA KIRIN CO LTD·Filed 2020·Granted May 17, 2022·0 cites·3 claims
- 3956US2023159662A1Antibody compositionKYOWA KIRIN CO LTD·Filed 2021·Application pending·0 cites
- 4056US2022088011A1Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibodyKYOWA KIRIN CO LTD·Filed 2021·Application pending·0 cites
- 4156US2020147188A1Therapeutic composition containing antithrombin gammaKYOWA KIRIN CO LTD·Filed 2019·Application pending·0 cites
- 4255US11208491B2Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibodyKYOWA KIRIN CO LTD·Filed 2018·Granted Dec 28, 2021·0 cites·10 claims
- 4354US2022324945A1Method for purifying antibody using adsorbentKYOWA KIRIN CO LTD·Filed 2020·Application pending·0 cites
- 4453US2023406926A1Bispecific antibody binding to cd3KYOWA KIRIN CO LTD·Filed 2021·Application pending·0 cites
- 4551US2021403971A1Method for preparing liquid mediumKYOWA KIRIN CO LTD·Filed 2019·Application pending·0 cites
- 4650US12280118B2IL-2 variantKYOWA KIRIN CO LTD·Filed 2018·Granted Apr 22, 2025·0 cites·13 claims
- 4750US11912775B2Anti-human CCR1 monoclonal antibodyKYOWA KIRIN CO LTD·Filed 2018·Granted Feb 27, 2024·0 cites·17 claims
- 4850US2021380684A1Antibody compositionKYOWA KIRIN CO LTD·Filed 2019·Application pending·0 cites
- 4948US11091545B2Methods of using an antibody to stabilize and analyze a BRIL fusion proteinKYOWA KIRIN CO LTD·Filed 2018·Granted Aug 17, 2021·0 cites·7 claims
- 5047US2022378923A1Bet degraderKYOWA KIRIN CO LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when KYOWA KIRIN CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →